Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms

BACKGROUND: Immunohistochemical (IHC) PD-L1 expression is commonly employed as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC). However, IHC evaluation methods are non-uniform and further studies are needed to optimize clinical utility. METHODS: We compared the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sigurjonsdottir, Gudbjörg, De Marchi, Tommaso, Ehinger, Anna, Hartman, Johan, Bosch, Ana, Staaf, Johan, Killander, Fredrika, Niméus, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566164/
https://www.ncbi.nlm.nih.gov/pubmed/37817263
http://dx.doi.org/10.1186/s13058-023-01724-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566164/
https://www.ncbi.nlm.nih.gov/pubmed/37817263
http://dx.doi.org/10.1186/s13058-023-01724-2

Ejemplares similares